Interceptor Plus
When axial chronic low back pain does not respond to conservative care, ablation of the intraosseous basivertebral nerve (BVN) that courses within the vertebral body may be an effective treatment for select patients, according to findings from a prospective, single-arm, multicenter study published in the February issue of The Spine Journal. The findings demonstrate that there is “an. Product Description Intacept Injectionis a medicine that is used for the treatment ofRheumatoid arthritis,Ankylosing spondylitis,Psoriatic arthritis,Spinal arthritis,Polyarticular juvenile idiopathic arthritis,Arthritisand other conditions.The complete list of uses. What Is Intacept 25mg Injection And What It Is Used For? Intacept 25mg Injection is an immunosuppressive agent used to treat autoimmune diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis. Etanercept What is Etanercept for: This medication is a tumor-necrosis factor (TNF) blocker, prescribed for ankylosing spondylitis (type of joint pain that affects your back), juvenile arthritis (arthritis-related condition that develops in children), psoriasis, and rheumatoid (inflammation of. Intacept Management Ltd T/A Intacept Security Registered Office Address: As above. Registered in England Company No: 2660680 VAT No: 576 8872 69.
John Vanderhout, a Founding Director and Co-Inventor of the IntaCept® Tag has been involved in the electrical industry for 35 years. He has been the owner and operator of Interact Data and Communication Pty Ltd based in Cooma NSW for the past 20 years. John has substantial experience providing Portable Appliance Testing & Tagging as a service to his company's customers. He has identified a need for the IntaCept® Tag based on direct feedback from customers and his first-hand knowledge of the Work Health & Safety compliance requirements of those customers. His company has many years of experience working in the electrical contracting industry. John and Mark Lynn, developed the idea of a total digital solution to PAT systems which is the IntaCept® Tag. John is passionate about assisting in the education of young people in the Cooma region and presently holds the position of Chairman of the Board of the Snowy Mountains Christian School.
Mark Lynn, a Founding Director and Co-Inventor of the IntaCept® Tag has 14 years Electrical and Control Systems Engineering experience in the mining, manufacturing, water, waste-water and construction industries. He provides Electrical Engineering consulting expertise to all stages of projects from feasibility through to construction, commissioning and on into full operational production. Mark runs an Electrical and Control Systems Engineering consulting business, Intelek Australia Pty Ltd. Mark has provided the technical design skills required for the initial development of the product.
Over the past 5 years Mark has been developing the concept of the IntaCept® Tag. In conjunction with John Vanderhout he has engaged specialists to assist the development of the product, with the goal of bringing an innovative and new product to market.
Iain has over 26 years of experience in the Telecoms and IT industry in a number of international markets including Australia, New Zealand, UK, USA, Malaysia and Singapore. During that time, he has held a number of senior financial and commercial management roles. He was Managing Director of ACN Pacific from January 2008 to late 2014 and is currently CFO & Company Secretary of Aggregato Global.
Iain is a Director and Member of the Audit, Risk & Compliance Committee of TIO Limited, Chairman of Jeenee Communications and an Advisory Board member for Tailors Mark Pty Ltd. Iain was also a Director of the Direct Selling Association of Australia between 2010 and 2014.
Ian joined the Board of IntaCept Limited in November 2015.
Lachlan has implemented organisational change and business growth projects for public, corporate and SME clients. Lachlan holds a number of post-graduate qualifications in business management including an MBA in Marketing from the University of New England (UNE) and a Graduate Diploma in Applied Finance and Investments (FINSIA).
Intussusception Symptoms
With over 15 years working in senior management roles, Lachlan brings business strategy, leadership and organisational development expertise to the senior management of the company. Lachlan is an Associate Member of the Institute of Independent Business International (IIB) that contributes an extensive global network of business advisors to the future of the company. The IIB believes in 'practical advice that works' when assisting businesses in the SME sector.
Demonstrates
Relief
Demonstrates
Relief
Demonstrates
Relief
Low Back Pain
Endplates
Vertebrogenic Low Back Pain
Procedure
Low Back Pain
Patient Education Website
Intracept.com
Patient Education Website
We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices.1 While the majority of patients with low back pain improve, up to 15% of these patients experience chronic low back pain.2
Today, patients with CLBP are treated with conservative treatments such as physical therapy or injections, medications such as opioids, or potentially surgical options including spinal fusion or total disc replacement. Unfortunately, conservative treatments do not provide adequate relief for the majority of patients and only a small percentage are surgically eligible.
The focus has traditionally been on the intervertebral discs as the primary source of CLBP, known as discogenic pain. Research published over the past 20 years has concluded that vertebral body endplates are a significant source of CLBP. This pain is referred to as vertebrogenic pain and is transmitted via the basivertebral nerve, which is found within the vertebral body.
Based on this research, Relievant developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.* Intracept, commercially available in the US, is supported by two Level I randomized controlled trials in addition to long-term durability data showing functional and pain improvements are maintained beyond 5 years.
We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices.1 While the majority of patients with low back pain improve, up to 15% of these patients experience chronic low back pain.2
Today, patients with CLBP are treated with conservative treatments such as physical therapy or injections, medications such as opioids, or potentially surgical options including spinal fusion or total disc replacement. Unfortunately, conservative treatments do not provide adequate relief for the majority of patients and only a small percentage are surgically eligible.
The focus has traditionally been on the intervertebral discs as the primary source of CLBP, known as discogenic pain. Research published over the past 20 years has concluded that vertebral body endplates are a significant source of CLBP. This pain is referred to as vertebrogenic pain and is transmitted via the basivertebral nerve, which is found within the vertebral body.
Based on this research, Relievant developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.* Intracept, commercially available in the US, is supported by two Level I randomized controlled trials in addition to long-term durability data showing functional and pain improvements are maintained beyond 5 years.
“The Intracept Procedure is a new, minimally invasive option to treat chronic vertebrogenic low back pain. The procedure has been proven to be safe and effective in clinical trials, and is much less invasive than typical surgical options to treat vertebrogenic pain.”
Jeffrey Fischgrund, MD, Chairman, Department of Orthopedics, Beaumont Hospital, Royal Oak and principal investigator of the SMART Trial
“The Intracept Procedure is a new, minimally invasive option to treat chronic vertebrogenic low back pain. The procedure has been proven to be safe and effective in clinical trials, and is much less invasive than typical surgical options to treat vertebrogenic pain.”
Intercept Definition
Jeffrey Fischgrund, MD, Chairman, Department of Orthopedics, Beaumont Hospital, Royal Oak and principal investigator of the SMART Trial
Comments are closed.